Mark Shlomchik

Title: Mark Shlomchik: Innovator in T Cell Receptor Cloning

Introduction

Mark Shlomchik is a prominent inventor based in Pittsburgh, PA (US). He has made significant contributions to the field of immunology, particularly in the area of T cell receptor (TCR) cloning. His innovative work has the potential to advance therapeutic strategies in various diseases.

Latest Patents

Mark Shlomchik holds a patent for "Methods and materials for cloning functional T cell receptors from single T cells." This patent outlines methods and materials involved in cloning functional TCRs from single T cells. It includes techniques for obtaining nucleic acid encoding a TCR from a single T cell and arranging that nucleic acid to form vectors designed to express a TCR. The patent also describes kits for obtaining nucleic acid encoding a TCR and methods for making such kits. Additionally, it provides collections of nucleic acid primers designed to amplify the entire coding sequence of both variable regions for each expressed V segment for functional αβ or γδ TCRs of a particular mammalian species.

Career Highlights

Mark Shlomchik is affiliated with the University of Pittsburgh, where he continues to engage in groundbreaking research. His work has garnered attention for its potential applications in immunotherapy and personalized medicine. He has been recognized for his contributions to the scientific community and has established himself as a leader in his field.

Collaborations

Mark has collaborated with notable colleagues, including Eduardo Schittler Neves and Alexander McIntyre Rowe. These collaborations have further enriched his research and expanded the impact of his innovations.

Conclusion

Mark Shlomchik's work in cloning functional T cell receptors represents a significant advancement in immunology. His innovative methods and materials have the potential to transform therapeutic approaches in treating various diseases.